Renal Cell Carcinoma: Achieving Complete Response

Sandy Srinivas, MD


January 31, 2022

Sandy Srinivas, MD, describes an experience in which a patient with renal cell carcinoma achieved a complete response following therapy with ipilimumab and nivolumab. Dr Srinivas notes that the results of the CheckMate 214 study give her hope that her patient will maintain a complete response.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.